AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma treatment Fasenra.

A Phase II investigator-led trial investigating AstraZeneca’s Fasenra (benralizumab) treating eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD) has ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal organ damage, a mid-stage trial has shown. Results of the phase 2 trial, published in ...

Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used ...